Study of SNX-5422 in TP53 Null Cancers

Summary

SNX-5422 is a pro-drug of SNX-2112, a potent, highly selective, small-molecule inhibitor of the molecular chaperone heat shock protein 90 (Hsp90). Initial in vitro evidence supports that SNX-5422 may be active against TP53 null tumors irrespective of tumor type .

Timeline

Start

2016-03

Primary completion

2016-10

Completion

2016-10

Drugs

Indications